Against the vibrant backdrop of Milan, a global hub for pharmaceutical excellence, the industry gathers to embrace a new chapter of industrial development. From October 6 to 8, 2026, the highly anticipated CPHI Milan (Centre for Pharmaceutical Ingredients Milan), a flagship global pharmaceutical exhibition, grandly kicked off at Fiera Milano, Italy. As an emerging innovative Chinese enterprise deeply rooted in the biotechnology sector, Shanghai Runkey Biotech Co., Ltd. showcased its core technologies, premium products and innovative comprehensive solutions at this premier international event. Leveraging this top-tier global platform, the company connected with worldwide industrial resources, demonstrating its robust corporate strength and global development vision as a leading Chinese biotech firm.

CPHI Milan: The Benchmark of the Global Pharmaceutical Industry

The Convention on Pharmaceutical Ingredients (CPHI) is one of the world’s largest, most professional and influential international exhibitions dedicated to the pharmaceutical industry, widely recognized as the barometer and vane of the global pharmaceutical sector. As the flagship overseas session of the annual CPHI series, CPHI Milan serves as a core platform integrating full industrial chain resources from across the globe.

The 2026 CPHI Milan boasts an unprecedented scale, gathering over 2,900 leading pharmaceutical enterprises from 166 countries and regions worldwide and attracting more than 62,000 industry experts, R&D scholars, procurement specialists and industrial practitioners. Its exhibition scope covers the entire pharmaceutical industrial chain, including active pharmaceutical ingredients (APIs), biopharmaceuticals, CDMO customized services, pharmaceutical equipment, pharmaceutical packaging and formulation R&D. The exhibition builds an international docking ecosystem integrating technology demonstration, academic exchange, business negotiation and industry trend insight. It also features specialized forums such as the Sustainable Development Summit and AI Pharmaceutical R&D Forum, hosting over 260 industry leaders to share cutting-edge insights and conduct in-depth discussions on critical industry topics including global pharmaceutical supply chain upgrading, green pharmaceutical manufacturing and intelligent R&D innovation.

Endowed with authoritative industry influence, comprehensive industrial chain coverage and high-quality global business resources, CPHI Milan has become a core gateway for pharmaceutical enterprises worldwide to expand overseas markets, access cutting-edge international technologies and build global cooperation systems. It also stands as an invaluable stage for Chinese biotech enterprises to go global and showcase their innovative capabilities.

Runkey Biotech Goes Global: Empowering International Market Integration with Innovative Strength

With years of in-depth cultivation in the cellulose ethers products, Shanghai Runkey Biotech Co., Ltd. focuses on the R&D, production and sales of HPMC, MCC, CMC, L-HPC, HPC, EC etc.. Backed by a sophisticated R&D system, stringent quality control standards and a mature supply chain system, the company’s products and services are widely applied in biomedicine, functional food, fine chemical and other fields. It has earned widespread recognition from domestic and international clients for its consistent product quality and innovative technological advantages.

The participation in CPHI Milan marks a crucial step for Runkey Biotech to advance its global strategy and expand into high-end overseas markets. In response to the global trends of green, refined and high-end development in the pharmaceutical industry, Runkey Biotech’s professional team engaged in extensive in-depth negotiations with global industry leaders, overseas buyers and research institutions on product innovation, technological iteration, cross-border cooperation and market expansion, accurately aligning with global market demands and exploring diverse cooperation opportunities.

Differentiating itself from traditional pharmaceutical enterprises, Runkey Biotech adheres to the core development philosophy of "technology-driven innovation and compliance-based quality assurance". Benchmarking against the highest international industry standards, the company continuously optimizes production processes, upgrades R&D technologies and improves quality management systems.

Deepening Innovation-driven Development, Fueling Global Pharmaceutical Industrial Upgrading

The global biopharmaceutical industry is currently in a period of rapid iterative development with increasingly fierce market competition, where technological innovation, compliant production and green development have become core industrial competitiveness. As a pivotal exchange hub of the global pharmaceutical industry, CPHI Milan not only provides a premium platform for enterprises to showcase strengths, but also enables Runkey Biotech to accurately grasp global industry trends and market pain points.

Through this exhibition, Runkey Biotech has successfully integrated with international cutting-edge technological concepts, further broadened its global development vision, accumulated high-quality overseas client resources and cooperative channels, and effectively enhanced its global brand influence. Moving forward, Shanghai Runkey Biotech Co., Ltd. will take this exhibition as a new starting point to continue its in-depth layout in the biotechnology track. The company will remain committed to R&D innovation, continuously polish product quality, optimize service systems and iterate core technologies.

Furthermore, Runkey Biotech will further deepen its global layout, actively integrate into the global pharmaceutical industrial chain, supply chain and innovation chain. With an open and cooperative attitude to connect with global high-quality resources, the company will deliver greater value for global partners through high-end Chinese manufacturing and innovative technical solutions, contributing sustained strength to the high-quality and sustainable development of the global biopharmaceutical industry.